secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0001437749-25-018591
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart doses first patient in 10,000-subject Phase 2b oral COVID-19 vaccine trial against mRNA comparator
--------------------------------------------------------------------------------

- First patient dosed in 10,000-participant portion of Phase 2b trial for oral pill COVID-19 vaccine candidate.
- Trial to assess relative efficacy, safety, and immunogenicity versus approved mRNA COVID-19 vaccine over 12 months.
- DSMB reviewed 400-participant sentinel cohort safety data and recommended study proceed without modifications.
- Project funded by BARDA/NIAID under Project NextGen with award valued up to $460.7 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925018591/0001437749-25-018591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925018591/vxrt20250527_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-018591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer